You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AOTF Based Spectro-Polarimetric Imaging System for Stand-off Chemical Detection
SBC: BRIMROSE TECHNOLOGY CORP Topic: CBD13104Our goal in this SBIR project is to develop a lightweight, low-power, inexpensive hyperspectral spectro-polarimetric imaging sensor for wide area standoff detection of chemical agents. The imaging system will employ an acousto-optic tunable filter (AOTF) that operates in the LWIR wavelength range. The sensor will have polarimetric imaging capabilities which, adds a valuable signature feature to im ...
SBIR Phase II 2019 Department of DefenseOffice for Chemical and Biological Defense -
Open-Path Spatial Ring Down Spectrometer for Chemical Vapor Detection
SBC: PHYSICAL SCIENCES INC. Topic: CBD171004Physical Science Inc. (PSI) will develop a new approach to chemical vapor detection based on a novel open-path sample cell design. The PhaseI system level model predicts SNR supporting a probability of detection of 95% and a MTBFA of 168 hours for all relevant CWAs and TICs at the10 minute negligible MEG level at a 20 s measurement time. In addition to robust detection, the system design can provi ...
SBIR Phase II 2019 Department of DefenseOffice for Chemical and Biological Defense -
High stretch, environmentally robust hybridsil, perfluoroelastomer barrier composits for CBRN protective ensembles
SBC: NANOSONIC INC. Topic: CBD181003Electro-optical infrared and long wavelength infrared detectors and sensors are increasingly important for the Chemical/Biological Defense community. Solid-state optical cooler materials are in demand for replacing mechanical closed cycle coolers used in current LWIR standoff sensors to achieve cryogenic temperatures. Recent advances in optical cooling of rare-earth doped materials are pointing to ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Durable Stretch Barrier Materials
SBC: LUNA INNOVATIONS INCORPORATED Topic: CBD181003The proliferation of weapons of mass destruction (WMDs) presents a serious security threat to U.S. and allied personnel around the world. Military personnel and first responders must be prepared to operate under a wide range of chemical, biological, radiological, nuclear (CBRN) threats. Commercially available CBRN protective suits are bulky offering little dexterity to the wearer, therefore new st ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Durable Stretch Barrier Materials
SBC: LaunchBay LLC Topic: CBD181003Chemical, Biological, Radioactive and Nuclear (CBRN) protective ensembles are widely used by the US Military and civilian first responders as the first line of defense for personnel working in contaminated environments. Many innovative products have been developed for the chemical protective clothing market in response to demand from the market place for improved performance. However, the need for ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Extended Release of Pyridostigmine Bromide for Effectively Combating Nerve Agent Exposure
SBC: INNOSENSE CORPORATION Topic: CBD181004Chemical warfare agents such as the lethal nerve agent soman are a major source of risk to military personnel. Currently, pyridostigmine bromide (PB) is the only FDA-approved pretreatment to counteract the effects of soman. The rationale behind PB administration is that it acts as a “temporary” inhibitor of AChE. This precludes nerve agents from irreversible inactivation of AChE, thereby mitig ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment
SBC: ZYMERON CORP Topic: CBD181004Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Stable Formulation of Nerve Agent Intoxication Countermeasures
SBC: LUNA INNOVATIONS INCORPORATED Topic: CBD181005In response to the defined need for minimizing the carry weight of combat teams while retaining capability, Luna Innovations is proposing the development of a stable formulation of atropine and scopolamine for use in an autoinjector to combat nerve agent intoxication. The combined formulation of atropine and scopolamine will allow for better treatment with more physiological coverage within the hu ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Dual Formulation of Atropine and Scopolamine with Enhanced Stability
SBC: Nano Terra, Inc. Topic: CBD181005The standard US military treatment for nerve agent exposure is application of up to three autoinjectors, each containing atropine sulfate and 2-pralidoxime, to counteract symptoms of nerve agent intoxication and restore acetylcholinesterase activity. This treatment increases survival rates after nerve agent exposure, however, seizures resulting from nerve agent poisoning are a common symptom that ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense -
Dual Formulation of Atropine/Scopolamine with Enhanced Stability
SBC: CMC PHARMACEUTICALS INC Topic: CBD181005CMC Pharmaceuticals, Inc. (Cleveland, OH) is proposing developing a stable, combination product of two small molecule drug candidates as a counter measure to chemical warfare nerve agents (NA). The combination product is expected to exploit complementary pharmacological profiles for optimal muscarinic receptor blockade and anticholinergic activity within the peripheral and central nervous system. ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense